JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 206.86 Billion KRW | 9.49% |
| 2022 | 188.93 Billion KRW | 11.26% |
| 2021 | 169.81 Billion KRW | -7.47% |
| 2020 | 183.52 Billion KRW | 7.81% |
| 2019 | 170.22 Billion KRW | 9.66% |
| 2018 | 155.23 Billion KRW | 8.1% |
| 2017 | 143.59 Billion KRW | 8.55% |
| 2016 | 132.29 Billion KRW | 5.03% |
| 2015 | 125.95 Billion KRW | 13.34% |
| 2014 | 111.12 Billion KRW | 25.4% |
| 2013 | 88.61 Billion KRW | -0.53% |
| 2012 | 89.09 Billion KRW | 5.91% |
| 2011 | 84.12 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 54.39 Billion KRW | -1.69% |
| 2024 Q1 | 55.33 Billion KRW | 3.16% |
| 2023 Q2 | 52.08 Billion KRW | 4.2% |
| 2023 Q3 | 51.14 Billion KRW | -1.82% |
| 2023 Q4 | 53.63 Billion KRW | 4.88% |
| 2023 FY | 206.86 Billion KRW | 9.49% |
| 2023 Q1 | 49.99 Billion KRW | -0.5% |
| 2022 Q4 | 50.24 Billion KRW | 5.27% |
| 2022 Q1 | 43.83 Billion KRW | -1.32% |
| 2022 Q2 | 47.12 Billion KRW | 7.5% |
| 2022 Q3 | 47.72 Billion KRW | 1.28% |
| 2022 FY | 188.93 Billion KRW | 11.26% |
| 2021 Q2 | 42.72 Billion KRW | 0.71% |
| 2021 FY | 169.81 Billion KRW | -7.47% |
| 2021 Q4 | 44.42 Billion KRW | 10.4% |
| 2021 Q1 | 42.42 Billion KRW | -4.97% |
| 2021 Q3 | 40.23 Billion KRW | -5.83% |
| 2020 Q3 | 46.33 Billion KRW | -2.57% |
| 2020 FY | 183.52 Billion KRW | 7.81% |
| 2020 Q4 | 44.64 Billion KRW | -3.65% |
| 2020 Q1 | 46.29 Billion KRW | 3.85% |
| 2020 Q2 | 47.56 Billion KRW | 2.75% |
| 2019 Q3 | 43.09 Billion KRW | 2.68% |
| 2019 FY | 170.22 Billion KRW | 9.66% |
| 2019 Q4 | 44.57 Billion KRW | 3.43% |
| 2019 Q2 | 41.97 Billion KRW | 3.45% |
| 2019 Q1 | 40.57 Billion KRW | 3.64% |
| 2018 Q4 | 39.14 Billion KRW | -2.78% |
| 2018 Q3 | 40.26 Billion KRW | 9.3% |
| 2018 Q1 | 38.97 Billion KRW | 2.59% |
| 2018 FY | 155.23 Billion KRW | 8.1% |
| 2018 Q2 | 36.84 Billion KRW | -5.46% |
| 2017 Q4 | 37.98 Billion KRW | 1.06% |
| 2017 Q3 | 37.58 Billion KRW | 11.25% |
| 2017 FY | 143.59 Billion KRW | 8.55% |
| 2017 Q2 | 33.78 Billion KRW | -1.33% |
| 2017 Q1 | 34.24 Billion KRW | 1.84% |
| 2016 Q2 | 33.86 Billion KRW | 1.9% |
| 2016 Q4 | 33.62 Billion KRW | 6.47% |
| 2016 Q3 | 31.57 Billion KRW | -6.75% |
| 2016 FY | 132.29 Billion KRW | 5.03% |
| 2016 Q1 | 33.23 Billion KRW | 9.22% |
| 2015 Q4 | 30.42 Billion KRW | -4.03% |
| 2015 Q3 | 31.7 Billion KRW | -9.14% |
| 2015 FY | 125.95 Billion KRW | 13.34% |
| 2015 Q2 | 34.89 Billion KRW | 0.0% |
| 2014 FY | 111.12 Billion KRW | 25.4% |
| 2013 FY | 88.61 Billion KRW | -0.53% |
| 2012 FY | 89.09 Billion KRW | 5.91% |
| 2011 FY | 84.12 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -50.762% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 81.726% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 67.599% |
| HANDOK Inc. | 522.74 Billion KRW | 60.428% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -52.808% |
| Yuhan Corporation | 1858.98 Billion KRW | 88.872% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 68.845% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -298.153% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 86.125% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -53.332% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 44.173% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -133.494% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -21.993% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 7.84% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -50.762% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -165.025% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -36.929% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -136.781% |
| JW Holdings Corporation | 928.07 Billion KRW | 77.711% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 65.567% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 87.609% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 72.364% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -3.312% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -14.438% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -5.355% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 71.522% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -50.762% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 86.341% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 84.959% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 72.364% |
| Yuhan Corporation | 1858.98 Billion KRW | 88.872% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 73.97% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 11.938% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 65.208% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 72.364% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 29.189% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 25.841% |
| CKD Bio Corp. | 160.35 Billion KRW | -29.003% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 60.744% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 42.715% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 10.214% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -3.312% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 76.487% |
| Boryung Corporation | 859.62 Billion KRW | 75.936% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -64.268% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 44.173% |